Diffuse Midline Glioma — Trials

Diffuse Midline Glioma — Trials · CancerIndex

Clinical trials

Registered studies

129 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 61
Recruiting: 32
Ph III recruiting: 1
Growth YoY: —
Industry share: 18%
Top sponsor: Nationwide Children's Hospital
Termination share: 43.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (23)

clinicaltrialsPublishedShowing 1–4 of 4 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06639607	PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma(PRiME II)	suspended	Phase 1 / Phase 2	68	Washington University School of MedicineOTHER	1	Sep 11, 2026	clinicaltrials
NCT06806228	Phase I Pilot Study to Evaluate the Anti-glioblastoma Effect of S-Gboxin in Standard Treatment of Glioblastoma/Diffuse Midline Glioma and Response to Treatment (Regardless of Mutation Status)	suspended	Phase 1	10	Petrov, Andrey